FDA deems blood clot drug derived from goat’s milk safe
NEW YORK Food and Drug Administration has decided that a blood-clot drug extracted from the milk of genetically engineered goats is safe.
The drug, GTC Biotherapeutics’ ATryn (recombinant human antithrombin), is made to treat hereditary antithrombin deficiency in patients undergoing surgery and childbirth, a blood-clotting disorder that can be fatal. GTC is working with Ovation Pharmaceuticals to develop and market the drug in the United States.
The FDA has accepted GTC’s regulatory application for ATryn, while European regulators have approved it.
General Mills donates to charity and advertises through NBC’s ‘Biggest Loser’
GOLDEN VALLEY, Minn. Major food manufacturer General Mills is backing NBC’s hit show “Biggest Loser” with its first-ever advertising slot for the show’s seventh season, which started Tuesday night. The spot will be viewed by approximately 8.6 million viewers, and fall 2008 showed a 2% rise in adult viewers ages 18 to 49, a demographic that advertisers often like to target. Nine other marketers from the show’s December season will also be advertising.
General Mills is also sponsoring a “Pound for Pound Challenge” in which the Cheerios and Progresso soup maker will be contributing 10 cents to Feeding America for every pound of weight loss pledged at biggestloser.com.
“This is our first integrated partnership of this kind,” said John Haugen, General Mills’ vice president of health and wellness. “We’re looking for a positive impact on all of our brands.”
Though popular (“Biggest Loser” averaged 8.9 million viewers last January), the show will be rivaling Fox’s incredibly successful “American Idol,” which begins next week and also airs Tuesday nights. Idol can bring in an audience of up to 25 million.
Adventrx faces further workforce cuts
SAN DIEGO After laying off 55 percent of its workforce, Adventrx is planning further reductions in its employees to extend its remaining cash reserves, the company announced Monday.
The company said that in the end, it will have 14 employees. It has also reduced and delayed spending on third-party consulting and vendor services, including contract manufacturing.
The remaining employees will evaluate options for the future and continue the company?s study of the drug candidate ANX-514 (docetaxel emulsion) and submitting an approval application for the candidate ANX-530 (vinorelbine emulsion).
“It’s never easy to let go employees, particularly those who have been with the company for many years and who have made contributions to the company,” Adventrx board chairman Jack Lief said in a statement.